2017 has not got off to a bullish start, with January’s total venture financing deal value barely making it half way past last year’s level. The biggest round, at $40m, went to preterm birth risk specialist Sera Prognostics, catching the eye of the largest lab services provider in the US, LabCorp.
[Editors' note: For more details about VC deals in 2016 and previous years, go to Medtech Insight's VC deal tracker: https://medtech.pharmamedtechbi.com/datasets/vc-funding]
January chocked-up 26 venture financing deals of $1m or more. That may only have been five deals fewer than a...
Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.
“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.
As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.
